Antennary fucosylations in plasma glycoproteins have been proposed to be a key biomarker for differentiating MODY patients. An international research project led by Ludger and Quadram to quantify fucosylation levels in patients found a good correlation and supports the development of a clinical diagnostic test in primary care settings.

Link to paper: